GlassScriptPhysician profile
Cori C Passer
NPI 1902902497
$13,581.59
in general payments reported to CMS, 2019-2025
37 companies · $3,433 in 2025
The $3,433 reported for 2025 was more than what 79% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,627 · 2020: $342 · 2021: $1,093 · 2022: $2,118 · 2023: $2,455 · 2024: $2,513 · 2025: $3,433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,248 · Education: $94.66 · Consulting Fee: $58.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,247.83 |
| Education | $94.66 |
| Consulting Fee | $58.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,692.92 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Regeneron Healthcare Solutions, INC. | $1,611.26 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,215.70 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $1,128.51 | 2019-2025 | |
| Genentech USA, INC. | $1,105.65 | 2019-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $894.56 | 2019-2025 | |
| Pfizer INC. | $532.47 | 2019-2025 | |
| Abbvie INC. | $508.83 | 2021-2024 | |
| Hospira, INC. | $473.95 | 2023-2025 | |
| Amgen INC. | $472.95 | 2021-2025 | Tezspire |
| Csl Behring | $437.71 | 2022-2025 | Hizentra, Haegarda, Andembry |
| Takeda Pharmaceuticals U.S.A., INC. | $429.47 | 2022-2025 | Eohilia, Takhzyro, Hyqvia |
| Leo Pharma INC. | $344.94 | 2022-2025 | Adbry |
| Grifols USA, LLC | $344.15 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Optinose US, INC. | $320.64 | 2019-2024 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cori Passer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.